Xcout IntelAadi Bioscience, Inc.
Aadi Bioscience, Inc. is a commercial-stage biopharmaceutical company headquartered in Morristown, New Jersey, focused on developing precision therapies for genetically defined cancers.
Subscribe to see Aadi Bioscience, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Aadi Bioscience, Inc. at a glance
Aadi Bioscience, Inc. is a biotechnology company headquartered in United States. It has raised at least $373.5M across the 5 funding rounds on record. Its most recent funding round raised $100M in March 2025. Xcout tracks 13 named people at Aadi Bioscience, Inc., including Bryan Ball (Executive Officer).
Aadi Bioscience, Inc. leadership
- Bryan BallExecutive Officer
- Dave LennonExecutive Officer
- David DornanExecutive Officer
- Scott GiacobelloExecutive Officer
- Anupam DalalDirector
- Baiteng ZhaoDirector
7 more named people on record for Aadi Bioscience, Inc., with roles, board committees and tenure — see the full roster →
Aadi Bioscience, Inc. funding rounds
At least $373.5M raised across the 5 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $100M | — | |
| SEC Form D filing | $72.5M | — | |
| SEC Form D filing | $155M | — | |
| Series A | $23M | 1 named | |
| Series A | $23M | 4 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Aadi Bioscience, Inc. competitors
A few of Aadi Bioscience, Inc.'s closest competitors — see the full list of competitors and alternatives →
Apeiron Therapeutics is a clinical-stage biopharmaceutical and precision oncology company focused on developing biomarker-driven therapeutics for cancer.
Edison Oncology Holding Corp is a clinical-stage biopharmaceutical company that develops first-in-class, small-molecule, biomarker-driven therapies to target major cancer markets. The company identifies, acquires, and advances underdeveloped drug candidates to address critical unmet needs for cancer patients with specific genetic mutations.
A2 Biotherapeutics, Inc. is a clinical-stage biotechnology research company headquartered in Agoura Hills, California. The company develops precision T-cell therapies designed to target solid tumors while sparing healthy tissue.
Affini-T Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Watertown, Massachusetts, specializing in the development of precision immunotherapies and T-cell therapies for cancer patients.
Blueprint Medicines Corporation is a global precision therapy company that invents life-changing medicines, operating as a Sanofi company.
Mirador Therapeutics, Inc. is a clinical-stage precision medicine company headquartered in San Diego, California, focused on developing first- and best-in-class next-generation therapeutics.
Get Aadi Bioscience, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Aadi Bioscience, Inc. in Xcout Intel
- 13 named people with titles, LinkedIn and board committees
- 5 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access